LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Inicio・Lista de Acciones・Atossa Genetics Inc

Atossa Genetics Inc

Cerrado

0.8 1.27

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.79

Máximo

0.81

Métricas clave
By Trading Economics
Ingresos	-1.7M -8.4M
Empleados	15
EBITDA	-1.3M -8.4M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+681.25% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	9.6M 108M
Apertura anterior	-0.47
Cierre anterior	0.8

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

0.7955 / 0.898 Soporte y Resistencia

Atossa Genetics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 nov 2025, 17:45 UTC

Ganancias

Principales Movimientos del Mercado

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Ganancias

Principales Movimientos del Mercado

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 nov 2025, 18:03 UTC

Ganancias

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 nov 2025, 15:43 UTC

Ganancias

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 nov 2025, 12:00 UTC

Ganancias

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 nov 2025, 09:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Charlas de Mercado

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Ganancias

Adquisiciones, fusiones, absorciones

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Ganancias

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Charlas de Mercado

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Charlas de Mercado

Ganancias

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Charlas de Mercado

Ganancias

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Charlas de Mercado

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Charlas de Mercado

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Charlas de Mercado

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Comparación entre iguales

Cambio de precio

Atossa Genetics Inc previsión

Precio Objetivo

By TipRanks

681.25% repunte

Estimación a 12 Meses

Media 6.25 USD 681.25%

Máximo 7.75 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Atossa Genetics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Atossa Genetics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.7955 / 0.898Soporte y Resistencia

Recent bullish events outweigh bearish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.